<DOC>
	<DOCNO>NCT01862874</DOCNO>
	<brief_summary>A study evaluate efficacy , immunogenicity , tolerability V501 ( quadrivalent Human Papilloma Virus [ HPV ] [ Type 6 , 11 , 16 18 ] L1 Virus-Like Particle vaccine , GARDASILâ„¢ ) healthy , 16- 26-year old Japanese male . The hypothesis test : 1 ) V501 reduces combine incidence HPV 6- , 11- , 16- , 18-related persistent infection compare placebo , 2 ) V501 reduces combine incidence HPV 6- , 11- , 16- , 18-related persistent infection , condyloma acuminata , penile/perianal/perineal intraepithelial neoplasia , penile , perianal , perineal cancer compare placebo .</brief_summary>
	<brief_title>Efficacy Tolerability Study V501 Japanese Males ( V501-122 )</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Japanese No clinical evidence gross genital lesion suggest sexuallytransmitted disease clinically present external genital warts Other inclusion criterion discuss investigator screen History know prior vaccination HPV vaccine plan receive one outside study History external genital wart History severe allergic reaction require medical intervention Received immune globulin bloodderived product past 6 month plan receive Month 7 study History splenectomy , currently immunocompromised , diagnosed immunodeficiency , Human Immunodeficiency Virus ( HIV ) , lymphoma , leukemia , systemic lupus erythematosus , rheumatoid arthritis , juvenile rheumatoid arthritis , inflammatory bowel disease , autoimmune condition Received immunosuppressive therapy past year , exclude inhale , nasal , topical corticosteroid certain regimen systemic corticosteroid Known thrombocytopenia coagulation disorder would contraindicate intramuscular injection Ongoing alcohol drug abuse within past 12 month</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>